Table 2.
Participant characteristics based on lung function tests
| All Participants | PFT | Incomplete/No PFT | p | |
|---|---|---|---|---|
| (n = 162) | (n = 112) | (n = 50) | ||
| Age | 0.8 | |||
| Mean (SD) | 73.8 (7.6) | 73.7 (7.4) | 74.1 (8.2) | |
| Median [IQR] | 74.0 [69–78] | 74.0 [69–78] | 74.0 [69–78] | |
| Age group, n (%) | 0.9 | |||
| < 65 | 19 (11.7) | 13 (11.6) | 6 (12.0) | |
| 65–75 | 82 (50.6) | 56 (50.0) | 26 (52.0) | |
| 75–85 | 48 (29.6) | 35 (31.3) | 13 (26.0) | |
| > 85 | 13 (8.0) | 8 (7.1) | 5 (10.0) | |
| Gender, n (%) | 0.7 | |||
| Male | 99 (61.1) | 70 (62.5) | 29 (58.0) | |
| Female | 63 (38.9) | 42 (37.5) | 21 (42.0) | |
| Race, n (%) | 0.4 | |||
| Caucasian | 145 (89.5) | 100 (89.3) | 45 (90.0) | |
| Other | 9 (5.6) | 8 (7.1) | 1 (2.0) | |
| Missing | 8 (4.9) | 4 (3.6) | 4 (8.0) | |
| Marital Status, n (%) | 0.04 | |||
| Married/De facto/Partner | 115 (71.0) | 85 (75.9) | 30 (60.0) | |
| Divorced/Widowed/Separated/Single | 45 (27.8) | 25 (22.3) | 20 (40.0) | |
| Missing | 2 (1.2) | 2 (1.8) | 0 (0.0) | |
| State of usual residence, n (%) | < 0.001 | |||
| NSW | 66 (40.7) | 57 (50.9) | 9 (18.0) | |
| VIC | 31 (19.1) | 21 (18.8) | 10 (20.0) | |
| QLD | 14 (8.6) | 5 (4.5) | 9 (18.0) | |
| SA | 25 (15.4) | 22 (19.6) | 3 (6.0) | |
| TAS | 16 (9.9) | 5 (4.5) | 11 (22.0) | |
| WA | 6 (3.7) | 0 (0.0) | 6 (12.0) | |
| ACT | 2 (1.2) | 2 (1.8) | 0 (0.0) | |
| NT | 2 (1.2) | 0 (0.0) | 2 (4.0) | |
| Remoteness area, n (%) | 0.1 | |||
| Major city | 99 (61.1) | 75 (67.0) | 24 (48.0) | |
| Inner regional | 43 (26.5) | 28 (25.0) | 15 (30.0) | |
| Outer regional/ Remote | 16 (9.9) | 8 (7.1) | 8 (16.0) | |
| Missing | 4 (2.5) | 1 (0.9) | 3 (6.0) | |
| Employment, n (%) | 0.9 | |||
| Full time/Part time/Unpaid work | 19 (11.7) | 14 (12.5) | 5 (10.0) | |
| Retired | 135 (83.3) | 92 (82.1) | 43 (86.0) | |
| Unemployed | 7 (4.3) | 5 (4.5) | 2 (4.0) | |
| Missing | 1 (0.6) | 1 (0.9) | 0 (0.0) | |
| Income ($), n (%) | 0.2 | |||
| < 400/week | 56 (34.6) | 39 (34.8) | 17 (34.0) | |
| 400–799/week | 50 (30.9) | 33 (29.5) | 17 (34.0) | |
| 800–1249/week | 15 (9.3) | 8 (7.1) | 7 (14.0) | |
| > 1250/week | 12 (7.4) | 11 (9.8) | 1 (2.0) | |
| Missing | 29 (17.9) | 21 (18.8) | 8 (16.0) | |
| Concession status, n (%) | ||||
| DVA | 7 (4.3) | 4 (3.6) | 3 (6.0) | 0.8 |
| Pensioner | 107 (66.0) | 71 (63.4) | 36 (72.0) | 0.4 |
| Seniors | 39 (24.1) | 20 (17.9) | 19 (38.0) | 0.01 |
| Other | 24 (14.8) | 14 (12.5) | 10 (20.0) | 0.3 |
| No card | 30 (18.5) | 25 (22.3) | 5 (10.0) | 0.1 |
| Comorbidities, n (%) | 1.0 | |||
| No | 33 (20.4) | 23 (20.5) | 10 (20.0) | |
| Yes | 129 (79.6) | 89 (79.5) | 40 (80.0) | |
| BMI kg/m2 (n = 154) | 0.1 | |||
| Mean ± SD | 28.1 (4.8) | 27.6 (4.3) | 29.3 (5.8) | |
| Median [IQR] | 28 [25–31] | 27 [25–30] | 28 [25–33] | |
| Missing | 8 (4.9) | 0 (0.0) | 8 (16.0) | |
| GAP stage, (n = 108) | < 0.001 | |||
| Stage I | 46 (28.4) | 46 (41.1) | 0 (0) | |
| Stage II | 52 (32.1) | 52 (46.4) | 0 (0) | |
| Stage III | 10 (6.2) | 10 (8.9) | 0 (0) | |
| Not classified | 54 (33.3) | 4 (3.6) | 50 (100) | |
| FVC, (n = 112) | < 0.001 | |||
| > 75 | 82 (50.6) | 82 (73.2) | 0 (0.0) | |
| 50–75 | 26 (16.0) | 26 (23.2) | 0 (0.0) | |
| < 50 | 4 (2.5) | 4 (3.6) | 0 (0.0) | |
| Not classified | 50 (30.9) | 0 (0.0) | 50 (100.0) | |
| CPI, (n = 108) | < 0.001 | |||
| < 40 | 38 (23.5) | 38 (33.9) | 0 (0.0) | |
| > 40 | 70 (43.2) | 70 (62.5) | 0 (0.0) | |
| Not classified | 54 (33.3) | 4 (3.6) | 50 (100.0) | |
| Medications, n (%) | ||||
| Antifibrotics | 96 (59.3) | 75 (67.0) | 21 (42.0) | < 0.001 |
| Other medications for used IPF (limited evidence) | 81 (50.0) | 54 (48.2) | 27 (54.0) | 0.61 |
| Medications not recommended for IPF treatment | 27 (16.7) | 12 (10.7) | 15 (30.0) | < 0.001 |
n number of participants, SD Standard deviation, $ Australian dollars, FVC forced vital capacity percent predicted, GAP Gender, Age, Physiology; CPI Composite Physiological Index. Not classified (includes participants with missing or incomplete PFTs), BMI Body Mass Index, IQR interquartile range, Antifibrotics medications include pirfenidone and nintedanib. Medications not recommended for IPF treatment include prednisolone, n-acetylcysteine, warfarin and azathioprine. Other medications used for IPF (limited evidence) includes anti-reflux drugs. NSW New South Wales, VIC Victoria, SA South Australia, QLD Queensland, TAS Tasmania, WA Western Australia, ACT Australian Capital Territory, NT Northern Territory
p value for appropriate test (t test or Chi-squared test). Bolded results represent statistically significant results (p < 0.05)